All the best,
Jackie Jura, November 2024

PS -- Below is an article penned by his enemy -- PHARMA -- explaining what they're up against if RFKjr is put in charge of guiding the nation's health policies. To make sure there's no misunderstanding, they spell out exactly what RFK-JR's goals are -- and they've hit the nail on the head.

With the election decided, one name is suddenly circulating in healthcare: Robert F Kennedy Jr. President-elect Donald Trump has promised Kennedy a large role in the new administration and signaled he could be in charge of guiding the nation's health policies. And Kennedy, who is not a public health or medical expert, has made it clear he intends to make sweeping changes in pharma and healthcare. This week, Kennedy outlined three goals directed to him from Trump: "clean up corruption", return agencies to the "gold standard" of science and "Make America Healthy Again". At the same time, Kennedy noted he and Trump "have not decided yet" on what his official role will be, but he didn't rule out the possibility of leading the Department of Health and Human Services or acting as a "White House health czar", potentially overseeing FDA, CDC, CMS, NIH and more. While his path in the Trump administration is vague, Kennedy's statements during his own run for president outlined his thoughts on public health. Here's what we know about Kennedy's stance on various health and pharma issues.

Capping drug prices: Like many political leaders on both sides of the aisle, Kennedy has signaled his support for capping drug costs. "Legislators should cap drug prices so that companies can't charge Americans substantially more than Europeans pay". Kennedy wrote in a Wall Street Journal op-ed in September. Kennedy pointed to Ozempic, Novo Nordisk's popular diabetes drug, as an example, noting that in Germany the drug costs less than one-tenth of its cost in the USA, where the list price is around $1,000 per month. During his first term, Trump issued an executive order that would have required Medicare to pay no more than the lowest prices in other OECD countries for drugs. CMS proposed what became known as "the most favored nation" model in November 2020, after Trump lost the election, but it was rescinded before the end of the year. While Trump has since backed away from the policy Kennedy's post position hints that he could revive the approach.

Vaccines: In the public health sphere, Kennedy is perhaps most well known for his anti-vaccine conspiracy theories. In particular, Kennedy wants to use federal health data to prove vaccines are unsafe, which could get them pulled from the market, Trump transition team officials said in October. However, Kennedy said this week he "won't take away anyone's vaccines" and instead promoted "choice". Trump has also teetered on his vaccine stance, stating he may still ban some vaccines once in office. Kennedy's anti-vaccine rhetoric has raised concern among some experts about what kind of health leader he'd become. "If [Kennedy] has a significant influence on the next administration, that could further erode people's willingness to get up to date with recommended vaccines", Dr Jerome Adams, who served as surgeon general in Trump's first administration, said at the American Public Health Association annual conference recently. Vaccine stocks also slid Wednesday morning. Pfizer, Moderna and BioNTech all saw share prices fall more than 2%, WSJ reported.

NIH funding: Kennedy also wants to upend funding for the National Institutes of Health and has touted a plan to "devote half of research budgets toward preventive, alternative and holistic approaches to health", he wrote in September. Notably, Kennedy said researchers currently don't have funding to understand underlying issues of disease, such as diet. He has also stated in other interviews that the entire nutrition department of the FDA, which oversees food quality and safety, "has to go" because "they're not protecting our kids".

Drug ads: Kennedy's distrust of the pharma industry is also underlined in his aim to revisit direct-to-consumer pharmaceutical ad guidelines. [example inserted below by jj]

In an op-ed, Kennedy suggested news channels may be influenced by drug ad revenue in their health news coverage. Total ad spending among the top 10 pharma companies was nearly $3 billion last year.

Obesity and chronic disease goals: Kennedy wants to take up the mantle of battling chronic disease under Trump's directive with the goal to make substantial improvements among children within two years. Trump has questioned whether "the overprescription of certain medications is to blame for obesity in the USA". And Kennedy has postulated that the pharma and healthcare industries profit from chronically sick children. Some experts have criticized Kennedy for this stance, arguing that effective medicines to treat chronic diseases are necessary and beneficial. Kennedy makes it sound as if treating chronic disease is a bad thing", Former CDC Director Tom Frieden wrote in an op-ed last month. "Nobody wants to have to take medicines to stay healthy, but it's dangerous to insinuate that medications are the problem". Kennedy's campaign office did not respond to a request for comment.

In the midst of the coronavirus pandemic, researchers have turned to existing medicines to see whether they can be repurposed to treat COVID-19... And surprisingly, the drug thalidomide is also being tested as a potential treatment for COVID-19. Thalidomide infamously caused thousands of birth defects to babies who were exposed to the drug after their mothers took it to treat morning sickness between 1958-1962. Despite its dark past, the drug has been repurposed in recent years, and is an approved treatment for multiple myeloma (a type of blood cell cancer) and complications of leprosy. Thalidomide was originally used as a sedative, and was later found to also be useful for treating severe morning sickness in the 1950s and 1960s. Tragically its use resulted in severe and rare birth defects in children, particularly to the limbs, but also damaged many other parts of the body.

Yet thalidomide has many different effects within the body -- which is why researchers are looking at it as a potential COVID-19 treatment. For example, it can inhibit the immune system's inflammatory response, making it effective against inflammatory conditions, including leprosy. It can also inhibit new blood vessel formation, making thalidomide potentially effective against cancers. It is currently approved to treat multiple myeloma. The drug can also protect the lungs, and has been effective in treating idiopathic pulmonary fibrosis. This is a life-threatening condition where the alveoli (which exchange oxygen and carbon dioxide molecules in the bloodstream) of the lungs are damaged, thickened and hardened, preventing them from working correctly. This leaves patients short of breath and with a persistent cough. Thalidomide has been shown to reduce the persistent cough and reduce the lung damage, improving patient life quality. It appears able to do this by blocking the inflammatory response. Thalidomide also appears to help relieve lung damage caused by the herbicide Paraquat. High doses of it can be toxic and result in lung inflammation, which causes scarring and reduced function. Animal studies suggest thalidomide can reduce the inflammatory response in lung tissue. Thalidomide has been found to protect against lung infections caused by the H1N1 virus in mice. H1N1 caused the 2009 flu pandemic. The study found that thalidomide improves the chances of survival for mice infected with H1N1 by reducing the body's inflammatory response. Evidence shows thalidomide could protect the lungs by reducing the body's inflammatory response, preventing damage of lung tissues and controlling the immune system. We know the coronavirus affects the lungs, causing pneumonia-like symptoms that result in inflammation, difficulty breathing and transporting oxygen around the body.

Several research groups wonder if thalidomide's ability to protect the lungs against other diseases could make it a potential treatment for COVID-19. Repurposing this existing drug to treat a new condition also means the dosage and potential side effects are already known. Preliminary evidence has found that using thalidomide in combination with glucocorticoids (which reduce immune response and inflammation pathways in the body) was able to successfully treat a patient suffering with pneumonia-like symptoms caused by COVID-19. However, this study is yet to be peer-reviewed. A clinical trial is also underway in China to investigate if thalidomide could be used to treat moderate and severe COVID-19 induced pneumonia. Patients testing positive for COVID-19 will be given thalidomide or a placebo medicine. The placebo should have no effect on COVID-19 progression and will then be compared with the thalidomide-exposed patients. It will still be some time before researchers know whether thalidomide is effective in treating some COVID-19 patients. However, thalidomide still has the ability to cause serious side effects. Thalidomide exposure during pregnancy can still harm the developing baby, something that happened recently in Brazil. Clinical use of thalidomide can also cause many other side-effects which include peripheral neuropathy in patients. This causes damage to the nerves in the body's extremities, causing pain. While such side-effects are usually associated with long-term use, any use of thalidomide needs to be carefully overseen by medical professionals. Using thalidomide in the treatment of COVID-19 might also give researchers a better understanding of the drug's effect in the body, and what other clinical conditions it could be useful for. Such work could also result, one day, in making safer forms of the drug that are an effective treatment without harmful side effects. However, it remains too early to determine its effectiveness in treating COVID-19.

The Global Thalidomide Market is estimated to grow at a CAGR XX% by 2025... This report features the market growth analysis and forecasting for the growth and revenue up to 2023 allied wigh the Thalidomide Industry... The Global Thalidomide Industry report also identifies major market players... The market is driven by Growing Drug & Alcohol Consumption, Enforcement of Stringent Laws Mandating Drug and Alcohol Testing, Presence of Government Funding in Major Markets and Regulatory Approvals & Product Launches and Services. Geographically, the Thalidomide Market has been segmented North America, Europe, APAC and now the market is dominated by North America.

Top Key Companies Anaylzed in Global Thalidomide Market are: *PFIZER *ALLERGEN *ALNYLAM *FIVE PRIME *ANGSTROM *ACCELERON *BIOCON *ENZON *CASI *CELGENE

Target Audience: *Thalidomide raw material suppliers and distributors *Thalidomide traders, distributors and dealers *Biotechnology-based organizations *Industry associations *End users *Research and consulting firms

The ongoing fight against COVID-19 has brought widespread public attention to FDA and its power to grant Emergency Use Authorizations (EUAs), which permits FDA to authorize formally unapproved medical products for emergency use against threats to public health and safety. Under article 564 of the Federal Food, Drug, and Cosmetic Act (FDCA), issuance of an EUA requires a determination by secretaries of the Department of Homeland Security, the Department of Defense, or the Department of Health and Human Services (HHS) that an emergency exists, as well as a declaration by the HHS Secretary that emergency circumstances exist warranting the issuance of EUAs. Unlike the strict standard of safety and efficacy used by FDA for ordinary product approvals, issuance of an EUA only requires FDA to conclude that:

     * it is reasonable to believe that a given product "may be effective" as an emergency countermeasure
     * the known and potential benefits of authorization outweigh the known and potential risks
     * no formally approved alternatives are available or adequate at the time

EUAs are playing a critical role in responding to the current COVID-19 pandemic, a situation evolving constantly with near-daily emergency authorizations of medical countermeasures. In the past eighteen months, FDA has issued an unprecedented number of EUAs for medical countermeasures that have yet to run the gauntlet of FDA's extensive formal approval process.

EUAs Against COVID-19: FDA's response to the COVID-19 pandemic has made the most significant use of EUA authorization since its inception. In February 2020, HHS Secretary Alex Azar declared the spread of SARS-CoV-2 a national health emergency warranting emergency authorization of diagnostic tests, followed by declarations warranting emergency authorization for a variety of other countermeasures. Since then, FDA has issued well over 400 EUAs for personal protective equipment, medical equipment, in vitro diagnostic products, drug products, and, most notably, vaccines (compared to a total of twenty-two EUAs in response to H1N1 in 2009). An EUA had never before been granted for a brand-new vaccine... The comparatively high stakes of administering a vaccine to people who are otherwise healthy led FDA to commit itself to heightened standards of review, or "EUA plus", in evaluating COVID-19 vaccines for emergency authorization. FDA has authorized three COVID-19 vaccines thus far: one by Pfizer-BioNTech on December 11, 2020; one by Moderna on December 18, 2020; and one by Johnson and Johnson on February 27, 2021. FDA amended the authorizations for the Pfizer-BioNTech and Moderna vaccines on August 12, 2021 to permit a third dose in solid organ recipients and others who are immunocompromised to a comparable degree. FDA granted the Pfizer-BioNTech vaccine formal approval on August 21, 2021. FDA's exercise of discretion in issuing EUAs has not been without controversy. The politicization of the pandemic...has added a political dimension to FDA's decision making as an administrative agency run by a presidential appointee. Many have criticized the White House for encroaching on FDA's independence and failing to uphold basic standards of respect for scientific evidence, technical expertise, and political independence...

EUAs and Vaccine Mandates: A public debate has erupted in the United States as to whether to mandate vaccination against COVID-19. On September 9, 2021, following FDA's approval of the Pfizer-BioNTech vaccine, the President announced a series of vaccine mandates affecting approximately 100 million employees in the federal government and private sector. Prior to FDA's decision, opponents of mandatory vaccination had attempted to support their positions by appealing to the fact that the three vaccines had been granted only emergency authorization rather than full formal approval. A number of organizations had suggested that they intended to wait until the vaccines were fully approved before making vaccination mandatory for their members. Even with one of the three vaccines having received full approval, the President's announcement has been met with bitter resistance... The EUA mechanism was intended as a way of getting countermeasures to people who need them fast. But a public that is reluctant to accept those countermeasures adds a new wrinkle to health policy. Not only does it frustrate FDA's efforts to respond as best they can to a national emergency, but it also poses a new question that may inform their decision making: will the use of a process viewed as being less rigorous than formal approval affect public trust?...

The entire world waits on pins and needles for a magic bullet to stop COVID-19 dead in its tracks. We cheer on researchers working around the clock to find a solution, a vaccine, or a cure. Despite our enthusiasm, we must take a cautious approach to medical research. Thalidomide's history is a grim reminder of what can go wrong when a drug comes to market without proper clinical trials and oversight... During the clinical trials for Thalidomide, animal tests did not study the effects of the drug during pregnancy. Rigorous worldwide guidelines for pharmaceutical testing were not in place as they are today. The result was over 10,000 children were born with severe and sometimes deadly Thalidomide-related disabilities around the world... It took years for the evidence of profound limb and other effects on babies to be linked back to maternal Thalidomide exposure. Later research uncovered the one compound, CPS49, that caused the severe limb defects (phocomelia) associated with Thalidomide exposure....

Every first-year medical student learns this fundamental principle of bioethics: "Primun non nocerere". It means, "First, do no harm"... When faced with a problem, one must weigh the benefits against the potential risks or unintended consequences. No matter how well-intentioned a treatment may be, one must always consider the unintended consequences. Medications have side effects. Surgical injuries occur. Weird and often unexpected outcomes show up during medical research. Viagra was originally developed for the treatment of high blood pressure until its side effect of inducing erections was discovered. In clinical trials, the term for an unintended consequence is referred to as an "adverse event". An adverse event is any untoward outcome experienced by a clinical trial patient. An adverse event is documented, tracked, and traced regardless of a known causal relationship with the pharmaceutical or medical device being evaluated. Event tracking is a key tool in Good Clinical Practice guidelines to uncover unexpected outcomes and protect patient safety...

More than 100 tests for COVID-19 are coming to the market under the FDA Emergency Authorization Act. Each test will have different degrees of accuracy. We must exercise caution before public health policy gets ahead of the scientific understanding of antibody testing. Research takes time. Anecdotal case reports and unpublished small cohort studies have value. These studies provide real-time data in an information vacuum to physicians in the field. A small study in New York yields interesting results regarding the use of heartburn medication in the treatment of COVID-19. These small clinical trials are only the first steps. They serve to identify the essential questions requiring further study in more robust trials. These studies do not mean we should all start taking medication for acid reflux. The Food and Drug Administration oversight started with the passage of the 1906 Pure Food and Drugs Act, an effort to protect consumers against misbranded food and medications. Many may be frustrated by FDA oversight slowing down the process in COVID-19 research.

MMR = MONEY-MAKING-RACKET = AUTISM

JFK DOC SAVED BABIES FROM THALIDOMIDE

COVID MASK-VAX OF THE BEAST

IN AFGHAN FIELDS

BIG BROTHER BIO-CHEM WARFARE

CORPORATE COMMUNIST CONSPIRACY IN 1984

JFK ASSASSINATION PUZZLE PIECES & RFK ASSASSINATION PUZZLE PIECES

*5.Big Brother Pyramidal New World Order & 35.Big Brother's Brotherhood

14.Scientific Experimentation & 16.Ministry of Truth (Lies) & 25.Prolefeed